Car-t cell therapy for severe lupus
Part of Immune system & allergy clinical trials.
This trial tests an experimental therapy called IC19 CAR-T cells, which are specially modified immune cells, for people with severe lupus that hasn't gotten better with standard treatments. The goal is to see if this therapy can calm the immune system and reduce lupus symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of systemic lupus erythematosus (SLE), often called lupus, based on standard medical criteria.
- You need to have tried at least two types of treatment: steroids with immunosuppressants (like cyclophosphamide or mycophenolate) and at least one biologic drug (like rituximab or belimumab) for at least 2 months, and your lupus is still active or has come back.
- Your age must be between 18 and 70 years.
- Your lupus activity score must be at least 8, and you must test positive for certain antibodies (like ANA or anti-dsDNA).
- Your vital organs (like bone marrow, liver, kidneys, and heart) need to be functioning well enough, as checked by blood tests and other evaluations.
- You should not have had CAR-T therapy or a stem cell/organ transplant before, and you must be willing to use birth control during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests whether a patient's own immune cells (T-cells) that are modified to target a protein called CD19 can help people with severe lupus that hasn't improved with other treatments. The goal is to reduce lupus activity and possibly achieve remission.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
This trial tests a personalized treatment called CD19 CAR T-cell therapy for people with severe lupus that hasn't improved with standard treatments. It uses your own immune cells to target and destroy the faulty cells causing lupus symptoms.
This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
This trial tests a new type of immunotherapy called CAR-T cell therapy for people with severe lupus that hasn't improved with usual treatments. The therapy uses your own immune cells to target and reduce the abnormal immune response that causes lupus symptoms.
Hear when a new Difficult to Treat Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.